In 2023, sales of the Genito Urinary System and Sex Hormones in Italy reached a certain level. From 2024, a forecasted decline trend is evident as values decrease from 387.9 million Euros in 2024 to 354.3 million Euros in 2028. The year-on-year declines are consistent, revealing a decreasing pattern with approximately -2.2% annually, derived from analyzing the projected year-over-year percentage changes. Moreover, this results in a compound annual growth rate (CAGR) of about -1.8% from 2024 to 2028.
Future trends to watch for include the potential impact of demographic changes and advances in medical research and development of new treatments, which could alter demand dynamics. Additionally, policy adjustments and healthcare funding allocations in Italy will be significant in shaping this market's direction. Monitoring these factors will be crucial for a comprehensive view of future market conditions.
